Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study

PurposeImmune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors may offer a first-line treatment for advanced hepatocellular carcinoma (HCC). In this phase 2 trial [registered with clinicaltrials.gov (NCT04052152)], we investigated the safety and efficacy of first-line anti-PD-1 a...

Full description

Bibliographic Details
Main Authors: Xiaofeng Chen, Wei Li, Xiaofeng Wu, Fengjiao Zhao, Deqiang Wang, Hao Wu, Yanhong Gu, Xiao Li, Xiaofeng Qian, Jun Hu, Changxian Li, Yongxiang Xia, Jianhua Rao, Xinzheng Dai, Qianwen Shao, Jie Tang, Xiangcheng Li, Yongqian Shu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
advanced hepatocellular carcinoma
sintilimab
anlotinib
anti-PD1
receptor tyrosine kinase
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.909035/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.909035/full

Similar Items